^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Ac-225 rosopatamab tetraxetan (CONV01-α)

    i
    Other names: CONV01-α, CONV 01-α, CONV 01 alpha, Actinium-225 radiolabeled J591, alpha-emitter Actinium-225 conjugated to the anti-PSMA antibody J591, 225Ac-J591, Ac 225 MOAB J591, Actinium-J591
    Associations

    News

    Trials
    Company:
    Dominari Holdings, Weill Cornell Medical College
    Drug class:
    Alpha radiation emitter, PSMA inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=76, Recruiting, Weill Medical College of Cornell University | Trial completion date: Jun 2028 --> Dec 2029 | Trial primary completion date: Jun 2026 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Xtandi (enzalutamide) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    3ms
    Re-treatment 225Ac-J591 for mCRPC (clinicaltrials.gov)
    P1, N=6, Completed, Weill Medical College of Cornell University | Active, not recruiting --> Completed
    Trial completion
    |
    CELLSEARCH®
    |
    Ac-225 rosopatamab tetraxetan (CONV01-α)
    5ms
    Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC (clinicaltrials.gov)
    P1/2, N=60, Active, not recruiting, Weill Medical College of Cornell University | Suspended --> Active, not recruiting | N=105 --> 60 | Trial completion date: Jun 2027 --> Jun 2026
    Enrollment closed • Enrollment change • Trial completion date
    |
    CELLSEARCH®
    |
    Ac-225 rosopatamab tetraxetan (CONV01-α)
    5ms
    Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=48, Suspended, Weill Medical College of Cornell University | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    CELLSEARCH®
    |
    lutetium zadavotide guraxetan (PNT2002) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    1year
    Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=76, Recruiting, Weill Medical College of Cornell University | Suspended --> Recruiting
    Enrollment open • Metastases
    |
    Keytruda (pembrolizumab) • Xtandi (enzalutamide) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    1year
    Re-treatment 225Ac-J591 for mCRPC (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting | N=18 --> 6
    Enrollment closed • Enrollment change
    |
    Ac-225 rosopatamab tetraxetan (CONV01-α)
    over1year
    Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=76, Suspended, Weill Medical College of Cornell University | Recruiting --> Suspended | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial suspension • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • Xtandi (enzalutamide) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    over1year
    Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC (clinicaltrials.gov)
    P1/2, N=105, Suspended, Weill Medical College of Cornell University | Recruiting --> Suspended
    Trial suspension • Metastases
    |
    Ac-225 rosopatamab tetraxetan (CONV01-α)
    over1year
    Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=48, Suspended, Weill Medical College of Cornell University | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date • Metastases
    |
    lutetium zadavotide guraxetan (PNT2002) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    2years
    PSMA PET Imaging Response Following a Single Dose 225AC J591 Therapy in Metastatic Castration Resistant Prostate Cancer: A Lesion and Patient Based Analysis (RSNA 2023)
    225Ac-PSMA-J591 effectively treats all metastatic categories. However, bone and visceral lesions may respond better than nodal lesions. Our findings need further validation but are informative for trial design and patient counselling.
    Clinical • Metastases
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    |
    Ac-225 rosopatamab tetraxetan (CONV01-α)
    2years
    7R01CA207645-03: Phase I Trial of 225Ac-J591 in Patients With mCRPC (clinicaltrials.gov)
    P1; Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Sep 2023
    Trial completion date • Trial completion • Metastases
    |
    CELLSEARCH®
    |
    Ac-225 rosopatamab tetraxetan (CONV01-α)
    2years
    Re-treatment 225Ac-J591 for mCRPC (clinicaltrials.gov)
    P1; Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    CELLSEARCH®
    |
    Ac-225 rosopatamab tetraxetan (CONV01-α)